Immunization, Hib3 in Lithuania
Lithuania: Immunization, Hib3 was 89.0% in 2024. ▲ Rising
Immunization, Hib3 in Lithuania, 1999–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children ages 12-23 months.
Analysis
In 2024, immunization, hib3 in Lithuania stood at 89.0%.
Compared with earlier readings it is down 1.1% on the previous year and down 4.3% over ten years.
Over the whole period, immunization, hib3 in Lithuania peaked at 98.0% in 2009 and was at its lowest, 2.0%, in 1999.
That places Lithuania 108th out of 191 countries with data for 2024, putting it in the middle of the range.
The long-run direction has been consistently rising across the 26 years of available data.
Immunization, Hib3 in Lithuania, year by year
| Year | % of children ages 12-23 months | Change |
|---|---|---|
| 1999 | 2.0% | — |
| 2000 | 2.0% | +0.0% |
| 2001 | 4.0% | +100.0% |
| 2002 | 5.0% | +25.0% |
| 2003 | 10.0% | +100.0% |
| 2004 | 35.0% | +250.0% |
| 2005 | 61.0% | +74.3% |
| 2006 | 94.0% | +54.1% |
| 2007 | 95.0% | +1.1% |
| 2008 | 96.0% | +1.1% |
| 2009 | 98.0% | +2.1% |
| 2010 | 95.0% | -3.1% |
| 2011 | 92.0% | -3.2% |
| 2012 | 93.0% | +1.1% |
| 2013 | 93.0% | +0.0% |
| 2014 | 93.0% | +0.0% |
| 2015 | 93.0% | +0.0% |
| 2016 | 94.0% | +1.1% |
| 2017 | 94.0% | +0.0% |
| 2018 | 92.0% | -2.1% |
| 2019 | 92.0% | +0.0% |
| 2020 | 91.0% | -1.1% |
| 2021 | 90.0% | -1.1% |
| 2022 | 90.0% | +0.0% |
| 2023 | 90.0% | +0.0% |
| 2024 | 89.0% | -1.1% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 1990s | 2.0% | 2.0% | 2.0% | 1 |
| 2000s | 50.0% | 2.0% | 98.0% | 10 |
| 2010s | 93.1% | 92.0% | 95.0% | 10 |
| 2020s | 90.0% | 89.0% | 91.0% | 5 |
Countries ranked near Lithuania
- 108 Burundi 89.0% compare
- 108 Colombia 89.0% compare
- 108 Netherlands 89.0% compare
- 108 New Zealand 89.0% compare
- 108 Nicaragua 89.0% compare
More health data for Lithuania
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.4537 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,909 deaths per 1,000 people (2090)
- Number of infants who die before age 1 5 deaths (2100)
- Population ages 40-44, male, annual growth rate 3.11 % change on previous year (2025)
- Population ages 40-44, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, male, per capita 0.0343 units per person (2025)
- Population ages 45-49, female, annual growth rate -1.68 % change on previous year (2025)
- Population ages 45-49, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 45-49, female, per capita 0.0308 units per person (2025)
Frequently asked questions
- What is immunization, hib3 in Lithuania?
- Immunization, hib3 in Lithuania was 89.0% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, hib3 recorded in Lithuania?
- The highest recorded value was 98.0% in 2009.
- What is the lowest immunization, hib3 recorded in Lithuania?
- The lowest recorded value was 2.0% in 1999.
- How does Lithuania rank for immunization, hib3?
- Lithuania ranks 108th out of 191 countries with data for 2024.
- Is immunization, hib3 rising or falling in Lithuania?
- Over the last ten years it is down 4.3%. The long-run trend across the full record is rising.
- Where does this Lithuania data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, Hib3 (% of children ages 12-23 months). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 26 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.